Gritstone Oncology Inc
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Gritstone Oncology Inc (GRTS) - Total Assets
Latest total assets as of June 2024: $142.54 Million USD
Based on the latest financial reports, Gritstone Oncology Inc (GRTS) holds total assets worth $142.54 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gritstone Oncology Inc - Total Assets Trend (2016–2023)
This chart illustrates how Gritstone Oncology Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Gritstone Oncology Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Gritstone Oncology Inc's total assets of $142.54 Million consist of 49.2% current assets and 50.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.7% |
| Accounts Receivable | $231.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how Gritstone Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gritstone Oncology Inc's current assets represent 49.2% of total assets in 2023, a decrease from 82.7% in 2016.
- Cash Position: Cash and equivalents constituted 36.7% of total assets in 2023, up from 26.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Gritstone Oncology Inc Competitors by Total Assets
Key competitors of Gritstone Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Gritstone Oncology Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Gritstone Oncology Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Gritstone Oncology Inc is currently not profitable relative to its asset base.
Gritstone Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.54 | 5.53 | 6.76 |
| Quick Ratio | 2.54 | 5.23 | 6.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $36.81 Million | $ 100.27 Million | $ 131.89 Million |
Gritstone Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Gritstone Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.17 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -26.2% |
| Total Assets | $177.77 Million |
| Market Capitalization | $2.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gritstone Oncology Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Gritstone Oncology Inc's assets decreased by 26.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Gritstone Oncology Inc (2016–2023)
The table below shows the annual total assets of Gritstone Oncology Inc from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $177.77 Million | -26.16% |
| 2022-12-31 | $240.75 Million | -13.43% |
| 2021-12-31 | $278.11 Million | +25.52% |
| 2020-12-31 | $221.57 Million | +20.16% |
| 2019-12-31 | $184.39 Million | -2.73% |
| 2018-12-31 | $189.56 Million | +61.60% |
| 2017-12-31 | $117.30 Million | +152.69% |
| 2016-12-31 | $46.42 Million | -- |